Chembio Diagnostics Appoints David Acheson, M.D. to its Board of Directors
December 17 2020 - 4:05PM
Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading
point-of-care diagnostic company focused on infectious diseases,
today announced the appointment of David Acheson, M.D. to the
Company’s Board of Directors.
“We are pleased to welcome David to our Board of
Directors. He adds directly applicable expertise in public health
and infectious disease management to our leadership team, and we
are confident his perspective will contribute meaningfully to our
long-term value creation strategy,” said Katherine L. Davis, Chair
of Chembio's Board of Directors. “We look forward to his leadership
and insights as we enter the next phase of growth for Chembio.”
Dr. David Acheson has served as the President and Chief
Executive Officer of The Acheson Group since founding the global
food safety consulting group in 2013. Previously he served as a
Partner and Managing Director of Leavitt Partners, where he founded
and managed the firm’s food safety services business. Prior to his
industry roles, Dr. Acheson served at the U.S. Food and Drug
Administration for eight years in various positions, progressing
from Chief Medical Officer of the Center for Food Safety and
Applied Nutrition to Associate Commissioner for Foods. Dr. Acheson
began his career practicing medicine in the United Kingdom and
later at the New England Medical Center, where he also served as an
Associate Professor for Tufts University while researching
foodborne pathogens.
Dr. Acheson received his Medical Doctor degree from the
University of London Medical School. He is a Fellow of the Royal
College of Physicians (London) and the Infectious Disease Society
of America.
“The unique features and versatility of Chembio’s
proprietary DPP technology platform make it uniquely suited for use
across the entire healthcare landscape. This is a transformational
time for the diagnostics industry as the global COVID-19 pandemic
sheds light on the true value of point-of-care testing,” said Dr.
Acheson. “I believe the DPP platform can not only make an impact as
a COVID-19 testing solution but also be leveraged to offer
innovative diagnostic tests for the future. I am excited about the
opportunity ahead for Chembio and to work with this team to drive
the adoption of the technology in the US and around the world.”
About the DPP Rapid Test
PlatformChembio’s proprietary DPP technology platform
provides high-quality, rapid diagnostic results in 15 to 20 minutes
using a small drop of blood from the fingertip or alternative
samples. Through advanced multiplexing, the DPP platform can detect
up to eight, distinct test results from a single patient sample,
delivering greater clinical value than other rapid tests. For
certain applications, Chembio’s easy-to-use, highly portable,
battery-operated DPP Micro Reader optical analyzer then reports
accurate results in approximately 15 seconds, making it well-suited
for decentralized testing where real-time results enable patients
to be clinically assessed while they are still on-site. Objective
results produced by the DPP Micro Reader reduce the possibility of
the types of human error that can be experienced in the visual
interpretations required by many rapid tests.
Chembio’s portfolio of DPP-based point-of-care
tests with FDA regulatory approvals include the DPP HIV-Syphilis
System (PMA approved), DPP HIV 1/2 Assay (PMA approved and CLIA
waived), DPP Zika IgM System (510(k)), and DPP Ebola Antigen System
(EUA). Additionally, DPP-based tests have received regulatory
approvals from the World Health Organization, CE-Mark, Agência
Nacional de Vigilância Sanitária (ANVISA), and other global
organizations, where they aid in the detection and diagnosis of
several other critical diseases and conditions.
All DPP tests are developed and manufactured in the
United States and are the subject of a range of domestic and global
patents and patents pending.
About Chembio DiagnosticsChembio
is a leading point-of-care diagnostics company focused on detecting
and diagnosing infectious diseases, including COVID-19, sexually
transmitted disease, and fever and tropical disease. Coupled with
Chembio’s extensive scientific expertise, its novel DPP technology
offers broad market applications beyond infectious disease.
Chembio’s products are sold globally, directly and through
distributors, to hospitals and clinics, physician offices, clinical
laboratories, public health organizations, government agencies, and
consumers. Learn more at www.chembio.com.
DPP is Chembio’s registered trademark, and the Chembio logo is
Chembio’s trademark. For convenience, these trademarks appear in
this release without ® or ™ symbols, but that practice does not
mean that Chembio will not assert, to the fullest extent under
applicable law, its rights to the trademark.
Contact: Philip TaylorGilmartin
Group(415) 937-5406investor@chembio.com
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Apr 2023 to Apr 2024